Steroid Sensitive Nephrotic Syndrome in Children

Status Terminated

Clinical Trial Summary

Idiopathic nephrotic syndrome (INS) is one of the most common glomerular pathologies in children and corticosteroid therapy is its most effective treatment. The total duration of treatment ranges anywhere from two to six months, generally about 3 months. The main objective of our study is to test the feasibility of a shorter total duration (two months) of corticosteroid therapy in patients who show a quicker treatment response to the initial treatment.

Clinical Trial Description

Idiopathic nephrotic syndrome (INS) is one of the most common glomerular pathologies in children and corticosteroid therapy is its most effective treatment. The main objective of our prospective, open-label, observational clinical cohort study is to test the feasibility of a shorter duration of corticosteroid therapy in patients who show a quicker treatment response. We hypothesize that the clinical outcomes in children with time to remission of ≤10 days and treated with only 8 weeks of corticosteroid therapy will not be significantly different as compared to those with time to remission of >10 days and treated with ≥12 weeks of standard corticosteroid therapy. Our specific aims are as follows: First, we will evaluate the time to first relapse after 8-week corticosteroid therapy in quick responders in comparison to the standard treatment of ≥12 weeks in slow responders. Second, we will assess the frequency of relapses during one year follow-up after completion of 8-week corticosteroid therapy in quick responders in comparison to the standard treatment of ≥12 weeks in slow responders. To complete the study successfully during the funding period of two years and to increase the generalizability of its results, the study will recruit 66 patients at six study participating sites in five countries, including U.S., India, China, Egypt, and Qatar. The sites have been carefully selected on the basis of their reputation, patient volume, research experience, and PI's personal rapport with the site investigators. The proposed study is innovative because it seeks a paradigm shift from 'one-size-fits-all' to an entirely new concept of individualized treatment duration based on "time to remission" with initial corticosteroid therapy. The proposed study is the first precision medicine initiative in the management of INS. The project is significant because of the potential to improve public health by decreasing the side effects of prolonged corticosteroid administration in about half of the patients diagnosed with INS. Our long-term objective is to develop additional novel therapeutic strategies to optimize the use of corticosteroids in the management of initial episode and relapses in children with INS. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03878914
Study type	Interventional
Source	Wayne State University
Contact
Status	Terminated
Phase	Phase 4
Start date	August 6, 2019
Completion date	October 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05044169` - Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome	N/A
Recruiting	`NCT05583942` - A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)	N/A
Recruiting	`NCT05588063` - taVNS for FRNS in Children	N/A
Recruiting	`NCT06125405` - Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome	Phase 3
Completed	`NCT04034316` - Reduce Immunosuppression With Atmp in NS ChildrEn	Phase 2
Completed	`NCT04048161` - Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome	Phase 4
Recruiting	`NCT06079788` - Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial.	Phase 3
Enrolling by invitation	`NCT04571658` - NEPTUNE Match Study
Recruiting	`NCT06417320` - Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years	Phase 4
Recruiting	`NCT05843968` - Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome	Phase 2
Recruiting	`NCT05734794` - Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial	Phase 3
Not yet recruiting	`NCT06130631` - Predictors of Steroid Response in Childhood Nephrotic Syndrome
Recruiting	`NCT03786263` - CHILDNEPH The Canadian Childhood Nephrotic Syndrome Study
Recruiting	`NCT05772871` - The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children	Phase 4
Recruiting	`NCT05505500` - Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.